Target intelligence / Profile preview

Nucleolar protein 3 (apoptosis repressor with CARD domain) (NOL3)

Target
NOL3
Molecular classification
Other (cytoplasmic/nucleolar anti-apoptotic regulatory protein; not a receptor, enzyme, or transporter), Caspase recruitment domain protein
01

Overview

Nucleolar protein 3 (NOL3, also known as ARC) is a multifunctional anti-apoptotic regulator encoded by the NOL3 gene[1][2][3]. It inhibits programmed cell death by blocking both extrinsic (death receptor-mediated) and intrinsic (mitochondrial-mediated) apoptosis pathways, interacting with key proteins such as FAS, FADD, caspase 8, BAX, and p53[1][2]. NOL3's activity extends to calcium-mediated cell death, oxidative stress-induced apoptosis, and TNF-induced necrosis. Dysregulation or overexpression of ARC/NOL3 is implicated in cancer chemoresistance, enhanced tumor progression, and poor prognosis; altered function or deletion can result in hematologic disorders like myeloproliferative neoplasm. ARC/NOL3 serves regulatory and survival roles in terminally differentiated tissues, especially in cardiac myocytes and neurons[2]. Although widely studied as a marker and survival factor, no direct inhibitors or drugs for NOL3 are currently in clinical use; its complex biology poses challenges for therapy targeting apoptotic pathways[1][2][3].

Other names
ARCNOPNOP30MYPFCMCARD2Muscle-enriched cytoplasmic proteinNucleolar protein of 30 kDaApoptosis repressor with CARD
02

Biological functions

Apoptosis inhibition (via extrinsic and intrinsic pathways)Calcium ion binding and bufferingRNA binding, possible involvement in RNA splicingRegulation of cell survival and cell cycle progressionVascular remodeling and cell proliferationNegative regulation of oxidative stress-induced apoptosisInhibition of TNF-induced necrosis
03

Disease associations

Cancer (breast, colon, nasopharynx, kidney, hematopoietic system)Chemoresistance in tumorsMyeloproliferative neoplasmEpilepsy, myoclonic juvenileFamilial myoclonusInflammatory conditions (e.g. inflammatory bowel disease)Vascular disease (remodeling, neointima formation)Neurodegeneration may be relevant as NOL3 is expressed in neurons
04

Safety considerations

Cancer cell resistance to chemotherapy and radiation due to NOL3/ARC expressionLoss of NOL3 may trigger myeloproliferative neoplasms resembling myelofibrosisBroad anti-apoptotic activity could lead to unwanted survival of malignant or abnormal cells
05

Biomarkers

ARC protein expression (prognostic in acute myeloid leukemia, breast cancer, colon, kidney, nasopharyngeal carcinoma)Aberrant ARC/NOL3 localization or abundance in tumor tissue

Beyond the preview

Go deeper on Nucleolar protein 3 (apoptosis repressor with CARD domain) (NOL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleolar protein 3 (apoptosis repressor with CARD domain) (NOL3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call